68 results about "Intra ocular pressure" patented technology

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

A glaucoma treatment apparatus including an imaging device capable of imaging the anterior segment of the eye, a treatment laser, an algorithm programmed to determine a location and a cross sectional area of a treatment based on a customized anatomy of the anterior segment of the eye including the trabecular meshwork (TM), the Schlemm's Canal (SC) and collector channels (CCS), obtained from pre-operative images of the anterior segment of the eye, a pre-operative intraocular pressure (IOP) level and a target IOP reduction as an inputs, and a processor configured to actuate the apparatus to create an outflow channel with a cross-sectional area and location or multiple outflow channels with multiple cross-sectional areas and locations from the anterior chamber (AC) to the SC across the TM, as determined by the algorithm to achieve the target intraocular pressure (IOP) reduction. Also disclosed is a method of reducing intraocular pressure in an eye.

The present invention relates to the technical field of pharmaceuticals, and in particular to a class of nitric oxide (NO) donor-containing compounds or pharmaceutically acceptable salts, a preparation method therefor, a pharmaceutical composition, and a use thereof in the treatment or prevention of an ocular hypertension-related ophthalmic disease and an optic nerve injury-related disease.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The present technology provides systems, devices, and methods for forming blebs to treat ocular hypertension or glaucoma. In some embodiments, a minimally invasive bleb formation device comprises an introducer sheath having a lumen extending longitudinally therethrough. The lumen has a distal end aperture insertable adjacent to a target tissue. The device further includes a wire positionable within the lumen of the introducer sheath. The wire has a first end portion, a second end portion, and an intermediate region between the first end portion and the second end portion. At least a segment of the intermediate portion is configured to extend through the distal end aperture to form a wire loop. The wire loop is moveable between a plurality of positions and is configured to disrupt and cauterize the target tissue.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

An ocular compression device with light directed through the sclera. The compression device may detachably house a lighting device that can be used to illuminate the eye area during ophthalmic surgery. Integrating the lighting device with the compression device during the procedure may reduce the number of hands required to perform the surgery. This may be particularly beneficial for ophthalmic surgery where the available surgical space is limited.

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The present application relates to a nitric oxide donor-type compound and use thereof in the preparation of a medicament for preventing and / or treating ophthalmic diseases such as glaucoma and ocular hypertension. The compound has a structure represented by formula (I), or is a stereoisomer, tautomer, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the structure represented by formula (I).

Disclosed in the present invention are an intraocular pressure sensing assembly and an intraocular pressure sensing method. The intraocular pressure sensing assembly comprises a lens body, an annular strain gauge, a plurality of regional strain gauges, and a sensing processing circuit, wherein the lens body has a central region and a peripheral region surrounding the central region; the annular strain gauge is arranged in the peripheral region and surrounds the central region; and the plurality of regional strain gauges are arranged at a plurality of predetermined positions in the peripheral region. In response to the intraocular pressure sensing assembly being worn on an eyeball of a subject, the sensing processing circuit measures the eyeball of the subject by means of the annular strain gauge to obtain first stress data, and measures the eyeball of the subject by means of the plurality of regional strain gauges to obtain a plurality of pieces of second stress data corresponding to the plurality of predetermined positions, and the sensing processing circuit further generates intraocular pressure distribution information on the basis of the first stress data and the plurality of pieces of second stress data.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The invention relates to a nitric oxide donor type compound and application thereof in preparation of drugs for preventing and / or treating ophthalmic diseases such as glaucoma and intraocular hypertension. The compound has a structure as shown in a formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the structure as shown in the formula (I).

The present disclosure relates to an eye disease implant device, and an eye disease implant device according to an embodiment of the present disclosure includes a tube including a hollow portion through which aqueous humor is drained, wherein one or more wings extending in a direction different from a longitudinal direction of the tube are formed on a portion of an outer surface of the tube. Also, the eye disease implant device may further include a body including a receiving space into which an end of the tube is inserted. In this case, the end of the tube may be inserted into the receiving space to be coupled to the body, or detached from the receiving space to be separated from the body.

The present disclosure pertains to the phakic refractive lenses such as toric lenses, an advanced posterior chamber floating phakic refractive lens (PRL) designed for the correction of severe refractive errors, including myopia, hyperopia, and astigmatism. This innovative lens can reduce or minimize complications commonly associated with traditional phakic intraocular lenses, such as intraocular pressure elevation, cataract formation, and iris pigment dispersion. The phakic refractive lenses such as the toric lenses described herein feature a buoyant, flexible structure with a central aperture to facilitate aqueous humor flow, creating a natural centering force that stabilizes the lens within the pupillary space.

The present disclosure relates to a travoprost sustained release biodegradable intracameral Implant comprising a biodegradable hydrogel and travoprost particles. The present disclosure also relates to travoprost particles optionally obtained by or obtainable by a process comprising a membrane emulsification step. The present disclosure also relates to a method of manufacturing travoprost particles, optionally wherein the method comprises a membrane emulsification step. The present disclosure also relates to a method of manufacturing a travoprost sustained release biodegradable intracameral implant. The present disclosure also relates to a method of treating an ocular disease, such as glaucoma or ocular hypertension, comprising administering the travoprost particles or inserting the intracameral implant of the present disclosure into an eye of a subject in need of treatment.

The invention discloses a traditional Chinese medicine composition for treating glaucoma-sleep-emotion co-disease and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials: 15g of fructus mume, 12g of schisandra chinensis, 12g of angelica sinensis, 12g of safflower carthamus, 6g of cassia twig, 15g of codonopsis pilosula, 15g of semen plantaginis, 6g of golden cypress and 6g of radix aconiti lateralis preparata. The formula of the traditional Chinese medicine composition is a mind-regulating and eyesight-improving formula obtained by the inventor in combination with traditional Chinese medicine classic and years of practical experience, and the formula can effectively reduce intraocular pressure of a glaucoma-sleep-emotion codisease patient, stabilize intraocular pressure rhythm, improve traditional Chinese medicine syndromes and sleep quality, and relieve anxiety and depression emotion. Therefore, the formula for regulating mind and improving eyesight is exact in curative effect, and has wide application prospects in simultaneous treatment of glaucoma and simultaneous regulation of brain and eyes.

The application discloses a teaching simulative human eyeball aqueous humor circulation model in the technical field of eyeball aqueous humor circulation models, which comprises a model box, an eyeball model assembly arranged in the model box, a functional body arranged at the top of the model box and a pump assembly arranged in the functional body. The eyeball model assembly comprises an eyeball wall, an eyeball and an optic nerve, and the eyeball wall is provided with a cornea at the front end. An iris is arranged on the side of the cornea close to the eyeball, the space between the cornea and the iris is an anterior chamber, the included angle between the cornea and the iris is an anterior chamber angle, the center of the iris is provided with a pupil, the iris is provided with a lens on the side close to the eyeball, the lens is provided with a zonular ligament around the lens, and the other end of the zonular ligament is fixedly connected with a ciliary body. The space between the iris and the lens constitutes a posterior chamber. The application has the advantages of simple structure, simulation of the process that the aqueous humor is retained in the eye to press the optic nerve when the anterior chamber angle is closed or the aqueous humor outflow passage is blocked, and convenience for medical students to understand the process that the optic nerve is pressed by the increased intraocular pressure when the aqueous humor passage is blocked.

The invention relates to a method and device for treating eye diseases, and belongs to the field of medical treatment. In order to treat ocular hypertension and glaucoma, a device for reducing intraocular pressure is provided, the device comprising: a plate having a first end and a second end, the plate comprising opposing first and second surfaces wherein the first surface comprises a series of fluid channels, the series of fluid channels are configured in an open cross-network pattern extending from a first end of the plate to a second end of the plate, the width of the first end of the plate being narrower than the width of the second end of the plate to enable the first end of the plate to be inserted into the anterior chamber of the patient, and wherein the second surface comprises a plurality of open cells formed by the fluid channels; a first coating on the first surface, the first coating conforming to a topography of the series of fluid channels, and a second coating on the second surface. The devices described herein can be used to reduce intraocular pressure and treat glaucoma.

The present invention relates to pharmaceutical composition comprising the beta 1 (β1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and / or a symptom associated therewith.

The application provides a kind of eye drop composition and its preparation method and application, belong to ophthalmic preparation technical field.The eye drop composition used in the application includes the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose, injection water;By compounding each component, a kind of eye drop capable of realizing brimonidine tartrate sustained release, prolonging the time of antihypertensive effect, and having the characteristics of reducing blinking discomfort, long-acting moisturizing, anti-inflammatory soothing, mild antiseptic, etc. is prepared;The eye drop of the application is helpful to glaucoma, high eye pressure, dry eye, postoperative inflammation or allergy, preservative-sensitive or preservative-allergic population, improves the quality of life, relieves the disease.

The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and / or cancer including colorectal cancer.The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the specification.

Disclosed herein are methods, devices, and systems for monitoring fluid outflow behavior of an eye of a subject, for example, during ocular surgery. Changes to intraocular pressure can reflect fluid outflow behavior. Fluid outflow behavior can be a critical factor in the successful outcome of a surgery and determining likelihood of post-operative side effects. Large fluctuations in intraocular pressure, ocular hypertension, and hypotony can be associated with vision loss or poor ocular health.

The invention belongs to the technical field of biological medicine, and particularly relates to a soluble microneedle patch for in-situ drug delivery of trabecular meshwork tissue and a preparation method and application of the soluble microneedle patch. The soluble microneedle patch comprises a fan-ring-shaped backing and a microneedle array arranged on the fan-ring-shaped backing; the micro-needle and the fan-ring-shaped backing are both prepared from polyvinyl alcohol (PVA), the PVA concentration for preparing the micro-needle and the fan-ring-shaped backing is 5%-25%, and the PVA concentration is obtained by weighing 0.5 g-2. 5 g of PVA powder and dissolving the PVA powder in 10 mL of pure water or PBS. The microneedle patch is suitable for delivery of various types of drugs, is expected to be used for treatment of various eye diseases including glaucoma, ocular hypertension, cataract, uveitis, conjunctivitis, xerophthalmia and the like, and has important clinical application value and commercial value.

The utility model belongs to the field of medical instruments, and particularly relates to a glaucoma hypertension intraocular pressure drainage device which comprises a tunnel knife used for manufacturing a sclera tunnel and an I-shaped drainage valve used for draining aqueous humor to reduce intraocular pressure, and the tunnel knife comprises a knife head and a knife handle arranged at the tail end of the knife head; a storage groove used for containing the I-shaped drainage valve is formed in the knife handle. A pipe cavity is formed in the I-shaped drainage valve in the length direction of the I-shaped drainage valve and penetrates through the I-shaped drainage valve. The tunnel knife can be used for accurately manufacturing a sclera tunnel with the length of 4mm and the width of 3mm, and the I-shaped drainage valve made of silica gel can be folded and can be implanted into the sclera tunnel through the injector. A tube cavity with the inner diameter being 60 micrometers is formed in the I-shaped drainage valve, aqueous humor can be drained to the position below the conjunctiva through the tube cavity in the drainage valve, intraocular pressure is reduced, damage of intraocular hypertension to eyes is reduced, the I-shaped drainage valve does not need to be fixed through suture, and the drainage device is simple, efficient, accurate and suitable for wide popularization.

The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.

The invention discloses an application of a miR-27a-3p inhibitor in preparation of a medicine for improving glaucoma. Glaucoma is a global main blinding neurodegenerative disease, retinal ganglion cell (RGC) apoptosis is a core pathological feature of the glaucoma, and existing intraocular pressure reduction treatment still cannot completely prevent neurodegenerative progress. Experiments prove that the miR-27a-3p inhibitor can be combined with 3 'UTR of PLK2 in a targeted mode, expression of the PLK2 is up-regulated, a PI3K / AKT signal channel is activated, and therefore RGC apoptosis is inhibited. A new glaucoma treatment strategy is provided, and the miR-27a-3p inhibitor can serve as an effective medicine to be used for improving glaucoma symptoms, protecting RGC and delaying disease progression and has good application prospects.

The application provides a VR design-based head-mounted intraocular pressure measuring device, which comprises a glasses shell, a display unit, two first lenses and two measuring members. The glasses shell comprises an outer shell and a support, the outer shell is internally provided with a containing cavity and an opening, the opening is communicated with the containing cavity, the support is arranged in the containing cavity, the support is provided with two mounting channels, the two mounting channels are spaced apart along a second direction, and the glasses shell is internally provided with a first air duct. The display unit is arranged in the containing cavity. The two first lenses are used for VR imaging in cooperation with the display unit. Each of the two measuring members is arranged in one of the mounting channels. Each of the measuring members is internally provided with a second air duct, a first end of the second air duct extends along a first direction and penetrates through the measuring member to a side surface of the measuring member facing the opening, and a second end of the second air duct is communicated with a first end of the first air duct. The device further comprises a gas supply unit communicated with the second end of the first air duct, a shooting unit for shooting an eye detection area, and a control unit for controlling the gas supply unit and acquiring intraocular pressure information according to a shooting result of the shooting unit.

The application discloses a method for establishing an angle-closure glaucoma animal model. The method comprises the following steps: performing mydriasis on an eye of an animal model after general anesthesia, performing local anesthesia on an eye surface of the model eye after 10 minutes; after the pupil of the model eye is reduced, eye gel is added to the eye surface; a semiconductor laser is used to uniformly hit a plurality of laser points at an iris margin; and eye drops are added to the eye surface after laser treatment. The method uses a 532nm laser to hit the iris margin, causes local edema of the iris margin, narrows a passage through which aqueous humor flows from the posterior chamber into the anterior chamber, and increases the pressure of the posterior chamber. The method can keep the high intraocular pressure of the established angle-closure glaucoma animal model between 20-30mmHg, the success rate is 70%, the high intraocular pressure can be maintained for more than one week, no wound is caused on the eye of the animal model, there is no inflammatory reaction on the eye surface, the cornea has no edema and new blood vessels, and the operation of the model can be completed within 10 minutes.